Skip to main content

Table 3 Distribution of clinical parameters according to the ERα/PI3K expression

From: Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant

Variable ERα/PI3K ≤9, no. (%) ERα/PI3K >9, no. (%) P
Age groups <50 years 75 (28.7) 36 (23.1) 0.206
>50 years 186 (71.3) 120 (76.9)
T. size <2 cm 157 (60.2) 84 (53.8) 0.207
>2 cm 104 (39.8) 72 (46.2)
LN invasion No 115 (44.1) 60 (38.5) 0.262
Yes 146 (55.9) 96 (61.5)
SBR grade Gr 1 54 (20.7) 25 (16.0) 0.069
Gr 2 130 (49.8) 68 (43.6)
Gr 3 77 (29.5) 63 (40.4)
ER status Negative 31 (11.9) 22 (14.1) 0.509
Positive 230 (88.1) 134 (85.9)
PR status Negative 60 (23.0) 45 (28.8) 0.182
Positive 201 (77.0) 111 (71.2)
HER2 status Negative 238 (93.0) 144 (92.3) 0.802
Positive 18 (7.0) 12 (7.7)
Breast Cancer subtype Luminal A 155 (59.4) 77 (49.4) 0.249
Luminal B 75 (28.7) 57 (36.5)
HER2 rich 6 (2.3) 5 (3.2)
TNBC 25 (9.6) 17 (10.9)
Type of adjuvant hormonal Tamoxifen 97 (57.1) 65 (49.2) 0.151
AI 129 (42.9) 67 (50.8)